Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INT-1B3 in Advanced Solid Tumors
NCT04675996Phase 1Terminated
- Sponsor
- InteRNA Technologies
- Start
- Dec 2020
- Primary completion
- Mar 2023
- Modality
- Nucleic Acid Therapeutics, Lipid-based Nanoparticles
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of INT-1B3 in solid tumor, sponsored by InteRNA Technologies. Primary endpoints: Incidence and severity of treatment-related adverse events and serious adverse events up to 24 months and Recommended Phase 2 Dose of INT-1B3 up to 24 months. Started Dec 2020; status: terminated.
02
Drugs
INT-1B3
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04675996.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04675996.